Thursday, 29 May 2008

Former Roche Boss Joins Med BioGene Board



MED BIOGENE INC.(TSX:V-MBI)
Basic shares: 29.1 million
Fully Diluted: 42.2 million



---------------------------------------------------------------------------------------------


Med BioGene has announced that Dr. Heiner Dreismann, former CEO of Roche Molecular Diagnostics joined its board of directors. This is an obvious coup for the company and speaks to the work that MBI is under taking. This is the type of announcement that the market should pay attention to as this type of talent is not easy to attract to a junior company unless it was on to something.

Med BioGene’s news release quickly touches on the Dr. Dreismann’s vast experience in the life sciences industry. Here is a more indepth perspective of his career.

He began his biotechnology career with Roehm and Haas in Darmstadt, Germany where he headed the genetic research and development effort to improve the yield of enzyme manufacturing fungal and bacterial strains. He joined F. Hoffmann La Roche AG in 1985, and held various national and international management positions, including head of manufacturing for microbiological diagnostics, head of R&D microbiological diagnostics and head of the Business Area Microbiology. After Roche’s acquisition of PCR technology in 1991, Dr. Dreismann made significant contributions to the organizational and financial growth of the Molecular Business Area, beginning with his role in 1991 as the head of the PCR Business Unit for Europe and the head of the strategic planning for PCR diagnostics.

He became head of the Integration Office for Diagnostics following the merger of Boehringer Mannheim and Roche Diagnostics in 1998; followed by positions as head of communications and public relations for Roche in Germany and head of business development/licensing for the Roche Diagnostics Division.

He was named President and CEO of Roche Molecular Diagnostics (RMD) in January 2001, Roche Diagnostics’ global business area responsible for the development, manufacture and distribution of PCR (polymerase chain reaction) products.

Dr. Dreismann serves on several boards of biotech and diagnostic companies. He is also a member of the New York Academy of Sciences and the American Society of Microbiology.

He received his M.A. in Biology from Westfalische Wilheims University in Munster, Germany and his Ph.D. in Microbiology/Molecular Biology from the University of Munster. He held a post-doctoral fellowship at the French Center for Nuclear Research in Saclay, near Paris, France.

To view the full news release, click here.